Methods for Treating HCV

Abstract

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

What is claimed is: 
     
         1 . A method of treatment for HCV genotype 1, comprising administering at least two direct acting antiviral agents (DAAs) to a patient infected with HCV genotype 1, wherein said treatment lasts for 4 or 6 weeks and does not include administration of either interferon or ribavirin to said patient, wherein said at least two DAAs comprise Compound 1 
       
         
           
           
               
               
           
         
       
       Compound 2 
       
         
           
           
               
               
           
         
       
       Compound 4 
       
         
           
           
               
               
           
         
       
       and another DAA, and wherein Compound 1 is administered with ritonavir. 
     
     
         2 . The method of  claim 1 , wherein said treatment lasts for 4 weeks. 
     
     
         3 . The method of  claim 1 , wherein said treatment lasts for 6 weeks. 
     
     
         4 . The method of  claim 1 , wherein said patient is a treatment-naïve patient. 
     
     
         5 . The method of  claim 2 , wherein said patient is a treatment-naïve patient. 
     
     
         6 . The method of  claim 3 , wherein said patient is a treatment-naïve patient. 
     
     
         7 . A method of modeling the relationship between DAA exposures and antiviral efficacy in HCV-infected subjects, wherein said modelling comprises modeling hepatocytes dynamics, infected cell dynamics, and viral dynamics. 
     
     
         8 . The method according to  claim 7 , wherein said modeling comprises resolution or simulation of equation 1:
     d  VLPoly/ dt =(1−μφ)*ρ*(1−Eff2)*Fit1*IPoly+μ*ρ*(1−Eff1)*IWT+φ*ρ*(1−Eff5)*Fit4*IPoly−Prot− c *VLPoly  Equation 1.